{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:59:59Z","timestamp":1790269199973,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Perinatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Collate patent ductus arteriosus (PDA) guidelines among Children\u2019s Hospitals Neonatal Consortium (CHNC) centers and identify variations in the diagnosis and management of hemodynamically significant PDA (hsPDA). Study Design: A descriptive survey requesting written PDA guidelines was sent to CHNC representatives from November 2023 to February 2024. Our study methods were performed in accordance with the survey guidelines and regulations of the CHNC. No PHI identifiers or institutional data were utilized for performing this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 44 centers, 38 (86%) responded; 25 (67%) provided written guidelines. Clinical signs of PDA were included in 18 (72%) guidelines, and 21 (84%) specified echocardiographic criteria for hsPDA. Ibuprofen was the most common first-line therapy, followed by acetaminophen and indomethacin. Most centers outlined a stepwise management approach including fluid restriction, diuretics, pharmacotherapy, and transcatheter closure. Surgical ligation was less frequently recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A majority of CHNC centers maintain written hsPDA guidelines incorporating clinical and echocardiographic criteria. Management emphasizes a stepwise approach from expectant to active management with pharmacotherapy and increasing adoption of transcatheter closure, highlighting evolving practice patterns in neonatal PDA care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41372-026-02910-8","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:54:03Z","timestamp":1790222043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variations in diagnosis and management of hemodynamically significant patent ductus arteriosus across neonatal intensive care units in the Children\u2019s Hospitals Neonatal Consortium"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-4821","authenticated-orcid":false,"given":"Sharada H.","family":"Gowda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-5834","authenticated-orcid":false,"given":"Philip T.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-3480","authenticated-orcid":false,"given":"Shannon","family":"Hamrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Keene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-0905","authenticated-orcid":false,"given":"Shawn","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan","family":"Rajgarhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-1858","authenticated-orcid":false,"given":"Rakesh","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-0974","authenticated-orcid":false,"given":"Molly K.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-8376","authenticated-orcid":false,"given":"Mark F.","family":"Weems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of CHNC Cardiac Focus Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2910_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1164\/rccm.202404-0694ED","volume":"210","author":"E Villamor","year":"2024","unstructured":"Villamor E, Gonzalez-Luis GE. Pulmonary hypertension and lung damage associated with prolonged exposure to patent ductus arteriosus in very preterm infants. Am J Respir Crit Care Med. 2024;210:254\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"2910_CR2","doi-asserted-by":"publisher","first-page":"e2345299","DOI":"10.1001\/jamanetworkopen.2023.45299","volume":"6","author":"E Villamor","year":"2023","unstructured":"Villamor E, van Westering-Kroon E, Gonzalez-Luis GE, Barto\u0161 F, Abman SH, Huizing MJ. Patent ductus arteriosus and bronchopulmonary dysplasia-associated pulmonary hypertension: a Bayesian meta-analysis. JAMA Netw Open. 2023;6:e2345299.","journal-title":"JAMA Netw Open"},{"key":"2910_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/chd.12702","volume":"14","author":"R Philip","year":"2019","unstructured":"Philip R, Nathaniel Johnson J, Naik R, Kimura D, Boston U, Chilakala S, et al. Effect of patent ductus arteriosus on pulmonary vascular disease. Congenit Heart Dis. 2019;14:37\u201341.","journal-title":"Congenit Heart Dis"},{"key":"2910_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1542\/peds.2025-071425","volume":"155","author":"N Ambalavanan","year":"2025","unstructured":"Ambalavanan N, Aucott SW, Salavitabar A, Levy VY. Patent ductus arteriosus in preterm infants. Pediatrics. 2025;155:5.","journal-title":"Pediatrics"},{"key":"2910_CR5","first-page":"43","volume":"ume 14","author":"S Gowda","year":"2024","unstructured":"Gowda S, Philip R, Weems M. Obstacles to the early diagnosis and management of patent ductus arteriosus. Res Rep Neonatol. 2024;ume 14:43\u201357.","journal-title":"Res Rep Neonatol"},{"key":"2910_CR6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41372-025-02257-6","volume":"45","author":"MF Weems","year":"2025","unstructured":"Weems MF, Ball MK, Zaniletti I, Habib S, Hamrick S, Grover TR, et al. Management of the patent ductus arteriosus among infants born at 23 to 32 weeks\u2019 gestation between 2011 to 2022: a report from in the Children\u2019s Hospitals Neonatal Consortium. J Perinatol. 2025;45:1540\u20137.","journal-title":"J Perinatol"},{"key":"2910_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jama.2025.23330","volume":"335","author":"MM Laughon","year":"2025","unstructured":"Laughon MM, Thomas SM, Watterberg KL, Kennedy KA, Keszler M, Ambalavanan N, et al. Expectant management vs medication for patent ductus arteriosus in preterm infants: the PDA randomized clinical trial. JAMA. 2025;335:588\u201399.","journal-title":"JAMA"},{"key":"2910_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapediatrics.2025.1025","volume":"179","author":"S Buvaneswarran","year":"2025","unstructured":"Buvaneswarran S, Wong YL, Liang S, Quek SC, Lee J. Active treatment vs expectant management of patent ductus arteriosus in preterm infants: a meta-analysis. JAMA Pediatr. 2025;179:877\u201385.","journal-title":"JAMA Pediatr"},{"key":"2910_CR9","first-page":"Cd013278","volume":"6","author":"S Mitra","year":"2025","unstructured":"Mitra S, Scrivens A, Fiander M, Disher T, Weisz DE. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev. 2025;6:Cd013278.","journal-title":"Cochrane Database Syst Rev"},{"key":"2910_CR10","doi-asserted-by":"publisher","first-page":"151721","DOI":"10.1016\/j.semperi.2023.151721","volume":"47","author":"RE Giesinger","year":"2023","unstructured":"Giesinger RE, Hobson AA, Bischoff AR, Klein JM, McNamara PJ. Impact of early screening echocardiography and targeted PDA treatment on neonatal outcomes in \u201c22-23\u201d week and \u201c24-26\u201d infants. Semin Perinatol. 2023;47:151721.","journal-title":"Semin Perinatol"},{"key":"2910_CR11","unstructured":"Roz\u00e9 JC, Cambonie G, Flamant C, Patka\u00ef J, M\u00fchlbacher T, Gascoin G, et al. Prophylactic treatment of patent ductus arteriosus with acetaminophen: a randomized clinical trial. JAMA Pediatr. 2026."},{"key":"2910_CR12","doi-asserted-by":"publisher","first-page":"106238","DOI":"10.1016\/j.earlhumdev.2025.106238","volume":"204","author":"R Mullaly","year":"2025","unstructured":"Mullaly R, Smith A, Franklin O, McCallion N, El-Khuffash A. Clinical and echocardiographic predictors of medical therapy failure for patent ductus arteriosus closure in preterm infants: Insights from a risk-based treatment approach. Early Hum Dev. 2025;204:106238.","journal-title":"Early Hum Dev"},{"key":"2910_CR13","doi-asserted-by":"crossref","unstructured":"Mitra S, Hebert A, Castaldo MP, Disher T, El-Naggar W, Dhillon S, et al. Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA). Arch Dis Child Fetal Neonatal Ed. 2026.","DOI":"10.1136\/archdischild-2026-330462"},{"key":"2910_CR14","doi-asserted-by":"crossref","unstructured":"Bischoff AR, Dias Maia P, McNamara PJ. Beyond diameter: redefining echocardiography criteria in trials of early PDA therapy. J Perinatol. 2025.","DOI":"10.1038\/s41372-025-02523-7"},{"key":"2910_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1056\/NEJMoa2207418","volume":"388","author":"T Hundscheid","year":"2023","unstructured":"Hundscheid T, de Boode WP. Expectant management or early ibuprofen for patent ductus arteriosus. Reply. N Engl J Med. 2023;388:1917\u20138.","journal-title":"N Engl J Med"},{"key":"2910_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41390-024-03525-5","volume":"97","author":"JT Wren","year":"2025","unstructured":"Wren JT, McNamara PJ Jr. More than a consult: integrating hemodynamics into neonatal care and research. Pediatr Res. 2025;97:1459\u201361.","journal-title":"Pediatr Res"},{"key":"2910_CR17","doi-asserted-by":"publisher","first-page":"105832","DOI":"10.1016\/j.earlhumdev.2023.105832","volume":"184","author":"A Smith","year":"2023","unstructured":"Smith A, Mullaly R, Franklin O, El-Khuffash A. Reproducibility of the EL-Khuffash PDA severity score and PDA diameter measurements in extremely preterm infants. Early Hum Dev. 2023;184:105832.","journal-title":"Early Hum Dev"},{"key":"2910_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMoa2207418","volume":"388","author":"T Hundscheid","year":"2023","unstructured":"Hundscheid T, Onland W, Kooi EMW, Vijlbrief DC, de Vries WB, Dijkman KP, et al. Expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med. 2023;388:980\u201390.","journal-title":"N Engl J Med"},{"key":"2910_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa2305582","volume":"390","author":"S Gupta","year":"2024","unstructured":"Gupta S, Subhedar NV, Bell JL, Field D, Bowler U, Hutchison E, et al. Trial of selective early treatment of patent ductus arteriosus with ibuprofen. N Engl J Med. 2024;390:314\u201325.","journal-title":"N Engl J Med"},{"key":"2910_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/jp.2016.11","volume":"36","author":"D Louis","year":"2016","unstructured":"Louis D, Torgalkar R, Shah J, Shah PS, Jain A. Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes. J Perinatol. 2016;36:544\u20138.","journal-title":"J Perinatol"},{"key":"2910_CR21","first-page":"278","volume":"29","author":"KV Katsivalis","year":"2024","unstructured":"Katsivalis KV, Jacobson JL, Bowker R, Berenz A, Hovey S, Click KW. Enteral feedings do not increase the risk of NEC in ELBW infants undergoing treatment of patent ductus arteriosus with acetaminophen. J Pediatr Pharm Ther. 2024;29:278\u201385.","journal-title":"J Pediatr Pharm Ther"},{"key":"2910_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jpeds.2013.01.057","volume":"163","author":"R Clyman","year":"2013","unstructured":"Clyman R, Wickremasinghe A, Jhaveri N, Hassinger DC, Attridge JT, Sanocka U, et al. Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus. J Pediatr. 2013;163:406\u201311.","journal-title":"J Pediatr"},{"key":"2910_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpeds.2018.09.012","volume":"205","author":"RI Clyman","year":"2019","unstructured":"Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Hakansson S, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019;205:41\u20138 e6.","journal-title":"J Pediatr"},{"key":"2910_CR24","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41372-024-02052-9","volume":"44","author":"S Mitra","year":"2024","unstructured":"Mitra S, Bischoff AR, Sathanandam S, Lakshminrusimha S, McNamara PJ. Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline. J Perinatol. 2024;44:1402\u20138.","journal-title":"J Perinatol"}],"container-title":["Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02910-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:02:13Z","timestamp":1790265733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02910-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":24,"alternative-id":["2910"],"URL":"https:\/\/doi.org\/10.1038\/s41372-026-02910-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9611532\/v1","asserted-by":"object"}]},"ISSN":["0743-8346","1476-5543"],"issn-type":[{"value":"0743-8346","type":"print"},{"value":"1476-5543","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MFW is a consultant and speaker for Abbott Congenital Heart for the Piccolo PDA\u2122 Occluder and an associate editor for Pediatrics in Review. PTL is a consultant and speaker for Abbott Congenital Heart for the Piccolo PDA\u2122 Occluder. SHG is on the editorial board of NeoReviews Plus. All other authors decline any conflicts of interest. PTL and MFW received speaker honorariums from Abbott Congenital Heart. Other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}